Lupus nephritis (LN) is a common and severe complication of systemic lupus erythematosus (SLE). Approximately 10% of patients with severe LN may progress to end-stage renal disease within 10 years of diagnosis, accompanied by high morbidity and mortality. In the field of treatment, glucocorticoids, antimalarials and other conventional agents have remained the mainstay since the early days, and new therapies emerged slowly until belimumab was approved. In recent years, there has been renewed progress in the research and treatment of SLE and LN, with a series of innovative therapies emerging, including biologics such as anti-B cell-activating factor antibodies, anti-CD20 antibodies, anti-CD40 antibodies, and anti-interferon antibodies, as well as small molecule kinase inhibitors. These developments have shifted treatment strategies towards more individualized and precise approaches. However, despite the expanding array of treatment options, many therapeutic needs remain inadequately met. This paper summarizes recent clinical trials and post-hoc analyses of LN, highlighting advances in promising therapeutic strategies.